By Lexaria Bioscience Corp. on Monday, 01 February 2021
Category: Pharmaceutical - BioTech

After successful raise of 11 million dollars, Lexaria Bioscience spells out R&D program for 2021

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives.

Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension and they are also looking at DehydraTECH with Antivirals for COVID-19.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Related Posts